Review article: Biliary tree malignancies

Erickson, Beth; Nag, Subir

doi:10.1002/(sici)1096-9098(199803)67:3<203::aid-jso12>3.0.co;2-2

Cited by 18 publications

(5 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It is estimated that 23,000 cases of cholangiocarcinoma are diagnosed in Japan every year, an incidence higher than that in western countries [1]. Although surgery is the only potentially curative treatment for cholangiocarcinoma, only 10% to 30% patients are candidates for surgery at presentation [2]. The majority of patients present with either locally advanced or distant metastatic disease.…”

Section: Introductionmentioning

confidence: 99%

“…Even for patients in whom curative resection is performed, the prognosis remains poor; local failure rates are high, and death from biliary obstruction, sepsis, and liver failure is common. For patients with unresectable cholangiocarcinoma, survival is poor, ranging from 3 to 9 months in those receiving medical management alone due to tumor aggressiveness [2-4]. …”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Clinical outcomes and toxicity of proton beam therapy for advanced cholangiocarcinoma

et al. 2014

View full text Add to dashboard Cite

BackgroundWe examined the efficacy and toxicity of proton beam therapy (PBT) for treating advanced cholangiocarcinoma.MethodsThe clinical data and outcomes of 28 cholangiocarcinoma patients treated with PBT between January 2009 and August 2011 were retrospectively examined. The Kaplan–Meier method was used to estimate overall survival (OS), progression-free survival (PFS), and local control (LC) rates, and the log-rank test to analyze the effects of different clinical and treatment variables on survival. Acute and late toxicities were assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0.ResultsThe median age of the 17 male and 11 female patients was 71 years (range, 41 to 84 years; intrahepatic/peripheral cholangiocarcinoma, n = 6; hilar cholangiocarcinoma/Klatskin tumor, n = 6; distal extrahepatic cholangiocarcinoma, n = 3; gallbladder cancer, n = 3; local or lymph node recurrence, n = 10; size, 20–175 mm; median 52 mm). The median radiation dose was 68.2 Gy (relative biological effectiveness [RBE]) (range, 50.6 to 80 Gy (RBE)), with delivery of fractions of 2.0 to 3.2 Gy (RBE) daily. The median follow-up duration was 12 months (range, 3 to 29 months). Fifteen patients underwent chemotherapy and 8 patients, palliative biliary stent placement prior to PBT. OS, PFS, and LC rates at 1 year were 49.0%, 29.5%, and 67.7%, respectively. LC was achieved in 6 patients, and was better in patients administered a biologically equivalent dose of 10 (BED10) > 70 Gy compared to those administered < 70 Gy (83.1% vs. 22.2%, respectively, at 1 year). The variables of tumor size and performance status were associated with survival. Late gastrointestinal toxicities grade 2 or greater were observed in 7 patients <12 months after PBT. Cholangitis was observed in 11 patients and 3 patients required stent replacement.ConclusionsRelatively high LC rates after PBT for advanced cholangiocarcinoma can be achieved by delivery of a BED10 > 70 Gy. Gastrointestinal toxicities, especially those of the duodenum, are dose-limiting toxicities associated with PBT, and early metastatic progression remains a treatment obstacle.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Clinical outcomes and toxicity of proton beam therapy for advanced cholangiocarcinoma

et al. 2014

View full text Add to dashboard Cite

show abstract

“…Gallbladder cancer (GBC) is one of the most common malignant neoplasms of the digestive tract (Erickson and Nag, 1998). GBC has a multifactorial etiology including gender, obesity, chronic cholecystitis, gallstones, and occupational exposure to specific chemicals (Moerman et al, 1997;Lowenfels et al, 1999;Pandey and Shukla, 2002;Serra et al, 2002).…”

Section: Introductionmentioning

confidence: 99%

Vitamin D receptor genetic variants are associated with susceptibility of gallbladder adenocarcinoma in a Chinese cohort

Li¹,

Yuan²,

Ning³

et al. 2014

Genet. Mol. Res.

View full text Add to dashboard Cite

ABSTRACT. The aim of this study was to test for the possible association between vitamin D receptor (VDR) genetic variants and susceptibility to gallbladder cancer (GBC). A total of 291 GBC cases were recruited and 396 gender-and age-matched healthy volunteers were enrolled as controls. The VDR gene polymorphisms were determined in all subjects. The genotype and the allele frequencies of ApaI, BsmI, and TaqI polymorphisms were not significantly different between GBC subjects and controls. However, the genotype and allele frequencies of the FokI C>T polymorphism were significantly different between GBC subjects and controls. The FokI TT genotype was in markedly higher frequency in GBC subjects compared to controls (38.14 vs 22.73%, P < 0.001). Using TT as the reference genotype, multivariate logistic regression analysis showed that CC genotype carriers had a higher risk of GBC (adjusted odds ratio (OR) = 3.423, adjusted P = 0.001) with adjustment for age, gender, smoking status, alcohol use, and gallstone presence, as well as the serum 1,25(OH)2D level. Carriers of the CT genotype also had a higher risk of GBC (adjusted OR = 1.992, adjusted

show abstract

“…http://dx.doi.org/10.15279/kpba.2015.20.2.71 stent insertion using percutaneous transhepatic biliary drainage (PTBD) or endoscopic retrograde biliary drainage is a widely accepted palliative procedure with the intent of symptomatic relief, such as obstructive jaundice. 5,6 Biliary stent insertion could result in slightly improved prognosis of patients by prevention of biliary stasis and hepatic failure.…”

mentioning

confidence: 99%

The Efficacy of Intraluminal Brachytherapy as Palliative Therapy of Hilar Cholangiocarcinoma

Park

Jeong²,

Kim³

et al. 2015

Korean J Pancreas Biliary Tract

View full text Add to dashboard Cite

Cholangiocarcinoma is the primary malignant tumor of the bile ducts which originates from cholangiocytes. 1 Surgical resection is the only curative therapy. Unfortunately, due to lack of symptoms until late in the disease, the majority of patients present with unresectable disease, typically resulting in advanced cholangiocarcinoma at the time of diagnosis. In addition, advanced age, poor performance status, acute illness, and/or systemic disease are considered inoperable in many cases. 2,3 In particular, in hilar cholangiocarcinoma, primary invasion of the portal vein and metastasis to the hepatic lobes occurs so frequently that surgical resection is impossible, and it is associated with a poor prognosis. 4 Biliary

show abstract

Review article: Biliary tree malignancies

Cited by 18 publications

References 32 publications

Clinical outcomes and toxicity of proton beam therapy for advanced cholangiocarcinoma

Clinical outcomes and toxicity of proton beam therapy for advanced cholangiocarcinoma

Vitamin D receptor genetic variants are associated with susceptibility of gallbladder adenocarcinoma in a Chinese cohort

The Efficacy of Intraluminal Brachytherapy as Palliative Therapy of Hilar Cholangiocarcinoma

Contact Info

Product

Resources

About